Company Filing History:
3 out of 1,744 
3 out of 5,089 
3 out of 141 
Years Active: 2021-2023
Title: Pierre-Joseph Royer: Innovator in Chronic Lung Allograft Dysfunction Prediction
Introduction
Pierre-Joseph Royer is a notable inventor based in La Montagne, France. He has made significant contributions to the field of medical research, particularly in the prediction and management of chronic lung allograft dysfunction (CLAD). With a total of three patents to his name, Royer has introduced innovative methods and compositions that hold promise for improving patient outcomes in lung transplant scenarios.
Latest Patents
Among his latest patents are innovative methods for predicting chronic lung allograft dysfunction. One such patent involves a prognostic method to determine a subject's risk of developing CLAD by measuring the expression levels of specific genes, namely POU2AF1 or BLK, in biological samples. If the expression levels fall below predetermined reference values, it may indicate that the subject is at risk of developing CLAD.
Another significant patent focuses on the measurement of TCL1A expression in biological samples. This research utilized large-scale gene expression profiling from whole blood cells of patients, helping identify early biomarkers of bronchiolitis obliterans syndrome (BOS). Through extensive microarray experiments, 47 genes were found to be differentially expressed between stable lung transplant recipients and those diagnosed with BOS. The TCL1A gene was highlighted as a predictive marker, showing promise in diagnosing conditions more than six months prior to clinical confirmation.
Career Highlights
Pierre-Joseph Royer has collaborated with esteemed institutions such as the National Center for Scientific Research and the University Hospital of Nantes. His work at these organizations has been crucial in advancing research in lung transplant immunology and pathology, contributing to a greater understanding of chronic transplant rejection.
Collaborations
Throughout his career, Royer has worked alongside distinguished colleagues, including Antoine Magnan and Sophie Brouard. Together, they have explored various aspects of lung transplant biology and have made valuable contributions to the scientific community through their research and innovations.
Conclusion
In summary, Pierre-Joseph Royer stands out as a pioneering inventor in the field of chronic lung allograft dysfunction. With his three patents, significant research accomplishments, and collaborations with leading institutions and professionals, Royer's work continues to impact the future of lung transplantation and patient care significantly. His innovative methods provide hope for earlier diagnosis and better management of conditions that affect lung transplant recipients.